- Home
- PMEC vs AXDX Comparison
PMEC vs AXDX Comparison
Compare PMEC & AXDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- AXDX
- Stock Information
- Founded
- PMEC 1984
- AXDX 1982
- Country
- PMEC Singapore
- AXDX United States
- Employees
- PMEC 2744
- AXDX N/A
- Industry
- PMEC
- AXDX Biotechnology: Laboratory Analytical Instruments
- Sector
- PMEC
- AXDX Industrials
- Exchange
- PMEC Nasdaq
- AXDX Nasdaq
- Market Cap
- PMEC 26.2M
- AXDX 28.3M
- IPO Year
- PMEC 2023
- AXDX 1996
- Fundamental
- Price
- PMEC $0.69
- AXDX $1.19
- Analyst Decision
- PMEC
- AXDX Hold
- Analyst Count
- PMEC 0
- AXDX 1
- Target Price
- PMEC N/A
- AXDX $1.00
- AVG Volume (30 Days)
- PMEC 323.0K
- AXDX 31.2K
- Earning Date
- PMEC 12-31-2024
- AXDX 03-27-2025
- Dividend Yield
- PMEC N/A
- AXDX N/A
- EPS Growth
- PMEC N/A
- AXDX N/A
- EPS
- PMEC N/A
- AXDX N/A
- Revenue
- PMEC $72,524,000.00
- AXDX $11,909,000.00
- Revenue This Year
- PMEC N/A
- AXDX $0.66
- Revenue Next Year
- PMEC N/A
- AXDX $3.36
- P/E Ratio
- PMEC N/A
- AXDX N/A
- Revenue Growth
- PMEC 5.07
- AXDX N/A
- 52 Week Low
- PMEC $0.49
- AXDX $0.73
- 52 Week High
- PMEC $4.15
- AXDX $2.09
- Technical
- Relative Strength Index (RSI)
- PMEC 46.18
- AXDX 46.90
- Support Level
- PMEC $0.69
- AXDX $1.07
- Resistance Level
- PMEC $0.74
- AXDX $1.22
- Average True Range (ATR)
- PMEC 0.08
- AXDX 0.10
- MACD
- PMEC -0.00
- AXDX -0.01
- Stochastic Oscillator
- PMEC 6.64
- AXDX 41.38
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About AXDX Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.